cagrisema phase 3 results 2025 semaglutide cagrilintide obesity Novo Nordisk's stock drops despite hitting goal of III trial New semaglutide and cagrilintide/semaglutide results

Standard measures such as body mass index may fail to detect this condition, underscoring the importance of comprehensive assessments that account for both muscle mass and body composition [76,77,78,79]

Diabetes Care 41(7):13911399

These products are not FDA-approved, have not been reviewed by FDA for safety and effectiveness, and FDA cautions they can lead to serious and potentially life-threatening adverse health consequences including infections and sepsis. Knock-off versions of semaglutide pose significant threats to peoples health and safety, a Novo Nordisk spokesperson said in an email to Healio | Endocrine Today

Raymond Bourey, MD, associate professor of medicine in the division of endocrinology at Washington University School of Medicine in St